344 related articles for article (PubMed ID: 27170161)
1. Investigational new drugs for brain cancer.
Staedtke V; Bai RY; Laterra J
Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
[TBL] [Abstract][Full Text] [Related]
2. Autophagy in brain tumors: a new target for therapeutic intervention.
Kaza N; Kohli L; Roth KA
Brain Pathol; 2012 Jan; 22(1):89-98. PubMed ID: 22150924
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.
Chelliah SS; Paul EAL; Kamarudin MNA; Parhar I
Molecules; 2021 Feb; 26(4):. PubMed ID: 33671796
[TBL] [Abstract][Full Text] [Related]
4. Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.
Okosun J; Packham G; Fitzgibbon J
Expert Opin Investig Drugs; 2014 Oct; 23(10):1321-32. PubMed ID: 24855903
[TBL] [Abstract][Full Text] [Related]
5. Advances on Epigenetic Drugs for Pediatric Brain Tumors.
Skouras P; Markouli M; Strepkos D; Piperi C
Curr Neuropharmacol; 2023; 21(7):1519-1535. PubMed ID: 36154607
[TBL] [Abstract][Full Text] [Related]
6. Clinical Targeting of Altered Metabolism in High-Grade Glioma.
Scott AJ; Lyssiotis CA; Wahl DR
Cancer J; 2021 Sep-Oct 01; 27(5):386-394. PubMed ID: 34570453
[TBL] [Abstract][Full Text] [Related]
7. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.
Das A; Fernandez NR; Levine A; Bianchi V; Stengs LK; Chung J; Negm L; Dimayacyac JR; Chang Y; Nobre L; Ercan AB; Sanchez-Ramirez S; Sudhaman S; Edwards M; Larouche V; Samuel D; Van Damme A; Gass D; Ziegler DS; Bielack SS; Koschmann C; Zelcer S; Yalon-Oren M; Campino GA; Sarosiek T; Nichols KE; Loret De Mola R; Bielamowicz K; Sabel M; Frojd CA; Wood MD; Glover JM; Lee YY; Vanan M; Adamski JK; Perreault S; Chamdine O; Hjort MA; Zapotocky M; Carceller F; Wright E; Fedorakova I; Lossos A; Tanaka R; Osborn M; Blumenthal DT; Aronson M; Bartels U; Huang A; Ramaswamy V; Malkin D; Shlien A; Villani A; Dirks PB; Pugh TJ; Getz G; Maruvka YE; Tsang DS; Ertl-Wagner B; Hawkins C; Bouffet E; Morgenstern DA; Tabori U
Cancer Discov; 2024 Feb; 14(2):258-273. PubMed ID: 37823831
[TBL] [Abstract][Full Text] [Related]
8. Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas.
Kolsteeg C; Hulleman E; Bianco J
Br J Cancer; 2022 Oct; 127(7):1193-1200. PubMed ID: 35715639
[TBL] [Abstract][Full Text] [Related]
9. Complications associated with immunotherapy for brain metastases.
Tran TT; Jilaveanu LB; Omuro A; Chiang VL; Huttner A; Kluger HM
Curr Opin Neurol; 2019 Dec; 32(6):907-916. PubMed ID: 31577604
[TBL] [Abstract][Full Text] [Related]
10. An Insight on Skin Cancer About Different Targets With Update on Clinical Trials and Investigational Drugs.
Vishwas S; Paul SD; Singh D
Curr Drug Deliv; 2024; 21(6):852-869. PubMed ID: 37496132
[TBL] [Abstract][Full Text] [Related]
11. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
Stitzlein LM; Adams JT; Stitzlein EN; Dudley RW; Chandra J
J Exp Clin Cancer Res; 2024 Jan; 43(1):12. PubMed ID: 38183103
[TBL] [Abstract][Full Text] [Related]
12. Considerations when treating high-grade pediatric glioma patients with immunotherapy.
Crotty E; Downey K; Ferrerosa L; Flores C; Hegde B; Raskin S; Hwang E; Vitanza N; Okada H
Expert Rev Neurother; 2021 Feb; 21(2):205-219. PubMed ID: 33225764
[TBL] [Abstract][Full Text] [Related]
13. [Systemic treatment of adult gliomas: a narrative review].
Mangel L
Magy Onkol; 2024 Mar; 68(1):67-75. PubMed ID: 38484377
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.
Ellingson BM; Wen PY; Cloughesy TF
Cancer J; 2021 Sep-Oct 01; 27(5):395-403. PubMed ID: 34570454
[TBL] [Abstract][Full Text] [Related]
15. The development of targeted new agents to improve the outcome for children with leukemia.
Bautista F; Van der Lugt J; Kearns PR; Mussai FJ; Zwaan CM; Moreno L
Expert Opin Drug Discov; 2016 Nov; 11(11):1111-1122. PubMed ID: 27670965
[TBL] [Abstract][Full Text] [Related]
16. Treatment advances in high-grade gliomas.
Chen X; Cui Y; Zou L
Front Oncol; 2024; 14():1287725. PubMed ID: 38660136
[TBL] [Abstract][Full Text] [Related]
17. NanoNail Gives Drug Response Readouts In Situ.
Cancer Discov; 2023 Nov; 13(11):2297-2298. PubMed ID: 37703445
[TBL] [Abstract][Full Text] [Related]
18. Emerging and investigational therapies for neuroblastoma.
Applebaum MA; Desai AV; Glade Bender JL; Cohn SL
Expert Opin Orphan Drugs; 2017; 5(4):355-368. PubMed ID: 29062613
[TBL] [Abstract][Full Text] [Related]
19. Focus on current and emerging treatment options for glioma: A comprehensive review.
Lucke-Wold B; Rangwala BS; Shafique MA; Siddiq MA; Mustafa MS; Danish F; Nasrullah RMU; Zainab N; Haseeb A
World J Clin Oncol; 2024 Apr; 15(4):482-495. PubMed ID: 38689623
[TBL] [Abstract][Full Text] [Related]
20. Glioma-on-a-Chip Models.
Ustun M; Rahmani Dabbagh S; Ilci IS; Bagci-Onder T; Tasoglu S
Micromachines (Basel); 2021 Apr; 12(5):. PubMed ID: 33926127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
